SG10201911076QA - Bycyclic heteroaryl derivatives as cftr potentiators - Google Patents
Bycyclic heteroaryl derivatives as cftr potentiatorsInfo
- Publication number
- SG10201911076QA SG10201911076QA SG10201911076QA SG10201911076QA SG10201911076QA SG 10201911076Q A SG10201911076Q A SG 10201911076QA SG 10201911076Q A SG10201911076Q A SG 10201911076QA SG 10201911076Q A SG10201911076Q A SG 10201911076QA SG 10201911076Q A SG10201911076Q A SG 10201911076QA
- Authority
- SG
- Singapore
- Prior art keywords
- heteroaryl derivatives
- cftr potentiators
- bycyclic
- bycyclic heteroaryl
- potentiators
- Prior art date
Links
- 125000001072 heteroaryl group Chemical group 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662435253P | 2016-12-16 | 2016-12-16 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG10201911076QA true SG10201911076QA (en) | 2020-01-30 |
Family
ID=62557188
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG10201911076QA SG10201911076QA (en) | 2016-12-16 | 2017-12-14 | Bycyclic heteroaryl derivatives as cftr potentiators |
| SG10201911221RA SG10201911221RA (en) | 2016-12-16 | 2017-12-14 | Bicyclic heteroaryl derivatives as cftr potentiators |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG10201911221RA SG10201911221RA (en) | 2016-12-16 | 2017-12-14 | Bicyclic heteroaryl derivatives as cftr potentiators |
Country Status (10)
| Country | Link |
|---|---|
| US (4) | US10131670B2 (en) |
| EP (1) | EP3554506B1 (en) |
| JP (1) | JP7150721B2 (en) |
| CN (1) | CN110300589B (en) |
| AU (2) | AU2017378324B2 (en) |
| CA (1) | CA3046968A1 (en) |
| MX (1) | MX391651B (en) |
| RU (1) | RU2753056C2 (en) |
| SG (2) | SG10201911076QA (en) |
| WO (1) | WO2018112149A1 (en) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UA125245C2 (en) | 2014-10-06 | 2022-02-09 | Вертекс Фармасьютикалз Інкорпорейтед | Modulators of cystic fibrosis transmembrane conductance regulator |
| EA201890949A1 (en) | 2015-11-25 | 2018-12-28 | Джилид Аполло, Ллс | ESSENTIAL ETHERIC ACETYL-COA-CARBOXYLASE INHIBITORS AND THEIR OPTIONS |
| PL3379933T3 (en) | 2015-11-25 | 2023-07-24 | Gilead Apollo, Llc | Fungicidal compositions containing derivatives of 2,4-dioxo-1,4-dihydrothieno[2,3-d]pyrimidine |
| ES2939833T3 (en) | 2015-11-25 | 2023-04-27 | Gilead Apollo Llc | Pyrazole ACC inhibitors and uses thereof |
| KR20180082557A (en) | 2015-11-25 | 2018-07-18 | 길리어드 아폴로, 엘엘씨 | Triazole ACC inhibitors and uses thereof |
| RS62670B1 (en) | 2016-09-30 | 2021-12-31 | Vertex Pharma | Modulator of cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulator |
| MD3551622T2 (en) | 2016-12-09 | 2021-03-31 | Vertex Pharma | Modulator of cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulator |
| EP3634402A1 (en) | 2017-06-08 | 2020-04-15 | Vertex Pharmaceuticals Incorporated | Methods of treatment for cystic fibrosis |
| WO2019018395A1 (en) | 2017-07-17 | 2019-01-24 | Vertex Pharmaceuticals Incorporated | Methods of treatment for cystic fibrosis |
| CA3071278A1 (en) | 2017-08-02 | 2019-02-07 | Vertex Pharmaceuticals Incorporated | Processes for preparing pyrrolidine compounds |
| EP3697774A1 (en) | 2017-10-19 | 2020-08-26 | Vertex Pharmaceuticals Incorporated | Crystalline forms and compositions of cftr modulators |
| JP7245834B2 (en) | 2017-12-08 | 2023-03-24 | バーテックス ファーマシューティカルズ インコーポレイテッド | A process for creating modulators of cystic fibrosis transmembrane conductance regulators |
| TWI810243B (en) | 2018-02-05 | 2023-08-01 | 美商維泰克斯製藥公司 | Pharmaceutical compositions for treating cystic fibrosis |
| MX2020008268A (en) | 2018-02-15 | 2020-09-21 | Vertex Pharma | Macrocycles as modulators of cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions thereof, their use in the treatment of cycstic fibrosis, and process for making them. |
| WO2019200246A1 (en) | 2018-04-13 | 2019-10-17 | Alexander Russell Abela | Modulators of cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulator |
| UY38630A (en) * | 2019-04-03 | 2020-10-30 | Vertex Pharma | MODULATING AGENTS OF THE TRANSMEMBRANE CONDUCTANCE REGULATOR OF CYSTIC FIBROSIS |
| EP3980121A1 (en) * | 2019-06-10 | 2022-04-13 | Novartis AG | Pyridine and pyrazine derivative for the treatment of cf, copd, and bronchiectasis |
| AU2020313422A1 (en) | 2019-07-15 | 2022-01-27 | Novartis Ag | Formulations of (S)-3-amino-6-methoxy-N-(3,3,3-trifluoro-2-hydroxy-2-methylpropyl)-5-(trifluoromethyl)picolinamide |
| TWI867024B (en) | 2019-08-14 | 2024-12-21 | 美商維泰克斯製藥公司 | Modulators of cystic fibrosis transmembrane conductance regulator |
| JP2022544383A (en) | 2019-08-14 | 2022-10-18 | バーテックス ファーマシューティカルズ インコーポレイテッド | Crystal forms of CFTR modulators |
| TW202120517A (en) | 2019-08-14 | 2021-06-01 | 美商維泰克斯製藥公司 | Process of making cftr modulators |
| IL300405A (en) | 2020-08-20 | 2023-04-01 | Univ Leland Stanford Junior | Methods for treating respiratory diseases characterized by mucus hypersecretion |
| IL303519A (en) | 2020-12-10 | 2023-08-01 | Vertex Pharma | Cystic fibrosis treatment methods |
| CN112876524B (en) * | 2021-01-26 | 2022-10-28 | 上海法默生物科技有限公司 | Preparation method of Reideciclovir intermediate |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE10135815A1 (en) * | 2001-07-23 | 2003-02-06 | Bayer Ag | Use of imidazo-triazinone derivative phosphodiesterase 5 inhibitors e.g. for treatment of cardiac insufficiency, psoriasis, diabetes, cancer, glaucoma, bladder disease, Parkinson's disease or pain |
| TWI329112B (en) * | 2002-07-19 | 2010-08-21 | Bristol Myers Squibb Co | Novel inhibitors of kinases |
| US20050008640A1 (en) * | 2003-04-23 | 2005-01-13 | Wendy Waegell | Method of treating transplant rejection |
| US7429596B2 (en) * | 2003-06-20 | 2008-09-30 | The Regents Of The University Of California | 1H-pyrrolo [2,3-D] pyrimidine derivatives and methods of use thereof |
| BRPI0619146A2 (en) * | 2005-12-02 | 2011-09-13 | Bayer Pharmaceuticals Corp | Substituted 4-amino-pyrroltriazine derivatives useful in the treatment of disorders and hyperproliferative diseases associated with angiogenesis |
| TW201307354A (en) * | 2005-12-29 | 2013-02-16 | Abbott Lab | Protein kinase inhibitors |
| AU2007347115A1 (en) * | 2006-04-04 | 2008-10-23 | The Regents Of The University Of California | PI3 kinase antagonists |
| CA2705303A1 (en) * | 2007-11-07 | 2009-05-14 | Foldrx Pharmaceuticals, Inc. | Modulation of protein trafficking |
| CN104800219A (en) * | 2010-02-05 | 2015-07-29 | 阿德弗里奥药品有限责任公司 | sGC stimulators or sGC activators alone and in combination with PDE5 inhbitors for the treatment of cystic fibrosis |
| UY34484A (en) * | 2011-12-15 | 2013-07-31 | Bayer Ip Gmbh | BENZOTIENILO-PIRROLOTRIAZINAS DISUSTITUIDAS AND ITS USES |
| EP3016955B1 (en) * | 2013-07-02 | 2018-03-07 | Rhizen Pharmaceuticals S.A. | Pi3k protein kinase inhibitors, particularly delta and/or gamma inhibitors |
| CN110337294B (en) * | 2016-11-18 | 2022-11-01 | 囊性纤维化基金会 | Pyrrolopyrimidines as CFTR potentiators |
-
2017
- 2017-12-14 SG SG10201911076QA patent/SG10201911076QA/en unknown
- 2017-12-14 EP EP17879832.8A patent/EP3554506B1/en active Active
- 2017-12-14 JP JP2019531417A patent/JP7150721B2/en active Active
- 2017-12-14 US US15/841,902 patent/US10131670B2/en active Active
- 2017-12-14 CA CA3046968A patent/CA3046968A1/en active Pending
- 2017-12-14 AU AU2017378324A patent/AU2017378324B2/en active Active
- 2017-12-14 CN CN201780086700.9A patent/CN110300589B/en active Active
- 2017-12-14 RU RU2019120990A patent/RU2753056C2/en active
- 2017-12-14 WO PCT/US2017/066317 patent/WO2018112149A1/en unknown
- 2017-12-14 MX MX2019007135A patent/MX391651B/en unknown
- 2017-12-14 SG SG10201911221RA patent/SG10201911221RA/en unknown
-
2018
- 2018-09-17 US US16/132,894 patent/US10208053B2/en active Active
- 2018-09-17 US US16/132,960 patent/US10377762B2/en active Active
-
2019
- 2019-07-09 US US16/506,883 patent/US10766904B2/en active Active
-
2021
- 2021-12-02 AU AU2021277702A patent/AU2021277702B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| RU2019120990A (en) | 2021-01-18 |
| RU2753056C2 (en) | 2021-08-11 |
| CA3046968A1 (en) | 2018-06-21 |
| MX2019007135A (en) | 2019-11-18 |
| US20190016728A1 (en) | 2019-01-17 |
| AU2021277702A1 (en) | 2021-12-23 |
| AU2017378324B2 (en) | 2021-09-02 |
| EP3554506A1 (en) | 2019-10-23 |
| BR112019012335A2 (en) | 2020-03-03 |
| US20180170938A1 (en) | 2018-06-21 |
| US10377762B2 (en) | 2019-08-13 |
| WO2018112149A1 (en) | 2018-06-21 |
| RU2019120990A3 (en) | 2021-01-18 |
| AU2021277702B2 (en) | 2023-11-30 |
| US20190016727A1 (en) | 2019-01-17 |
| CN110300589B (en) | 2023-03-10 |
| JP2020502103A (en) | 2020-01-23 |
| US20190330219A1 (en) | 2019-10-31 |
| US10766904B2 (en) | 2020-09-08 |
| US10208053B2 (en) | 2019-02-19 |
| AU2017378324A1 (en) | 2019-06-27 |
| EP3554506A4 (en) | 2020-06-10 |
| SG10201911221RA (en) | 2020-02-27 |
| MX391651B (en) | 2025-03-21 |
| US10131670B2 (en) | 2018-11-20 |
| EP3554506B1 (en) | 2021-04-28 |
| JP7150721B2 (en) | 2022-10-11 |
| CN110300589A (en) | 2019-10-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG10201911076QA (en) | Bycyclic heteroaryl derivatives as cftr potentiators | |
| IL266668A (en) | Pyrrolopyrimidines as cftr potentiators | |
| ZA201800826B (en) | Substituted oxopyridine derivatives | |
| IL246474A0 (en) | Heteroaryl substituted nicotinamide compounds | |
| EP3215147A4 (en) | Neuro-attenuating ketamine and norketamine compounds, derivatives thereof, and methods | |
| EP3248721A4 (en) | Bit | |
| EP3253753A4 (en) | Ergoline compounds and uses thereof | |
| EP3352758A4 (en) | Deuterated cftr potentiators | |
| RS62626B1 (en) | Quinolin-2-one derivatives | |
| ZA201802411B (en) | Indolin-2-one derivatives | |
| EP3476510A4 (en) | Drill | |
| ZA201804966B (en) | 2-oxindole compounds | |
| ZA201807129B (en) | Griseofulvin compound | |
| EP3294976A4 (en) | Improved blind | |
| EP3350402A4 (en) | Drilling device | |
| EP3434149A4 (en) | Reassemblable crib | |
| IL254711A0 (en) | Indole derivatives | |
| HUP1600234A2 (en) | Mdr-reversing 8-hydroxy-quinoline derivatives | |
| EP3101004A4 (en) | Bipyridyl compound | |
| EP3112343A4 (en) | Amide derivatives | |
| EP3440054A4 (en) | Pyrrole derivatives | |
| EP3244887A4 (en) | 5-methoxytryptophan and its derivatives and uses thereof | |
| PT3319956T (en) | Substituted oxopyridine derivatives | |
| HK1230588A1 (en) | Heteroaryl substituted nicotinamide compounds | |
| AU2016901625A0 (en) | Trestle |